| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $757K | — | +38.7% |
| R&D Expense | $598K | — | +36.7% |
| SG&A Expense | $1.9M | — | +3.7% |
| Operating Income | -$2.3M | — | -4.9% |
| Pre-tax Income | -$2.2M | — | -3.2% |
| Income Tax | $0 | — | — |
| Net Income | -$2.2M | +73.2% | -3.4% |
| EPS (Basic) | -$0.42 | — | +52.8% |
| EPS (Diluted) | -$0.42 | — | +52.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.9M | -35.5% | +242.3% |
| Accounts Receivable | $952K | +1.4% | +40.3% |
| Current Assets | $5.3M | -28.6% | +110.0% |
| Total Assets | $9.7M | -13.4% | +47.0% |
| Current Liabilities | $1.0M | +6.1% | -7.8% |
| Long-term Debt | $1.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.9M | — | -20.6% |
| Capital Expenditures | $23K | — | -38.3% |
| Investing Cash Flow | -$316K | — | -37.1% |
| Financing Cash Flow | $0 | — | -100.0% |
| Free Cash Flow | -$1.9M | — | -19.2% |
| +11.3% |
| Total Liabilities | $2.4M | +2.0% | +0.6% |
| Stockholders' Equity | $7.2M | -17.7% | +75.8% |